Painweek Booth Presentation: The Clinical Utility of Pharmacogenetic Testing in Pain Management
Variation in response to pain medication may be explained or predicted by genetics. Genotype-phenotype information can guide pre-therapeutic evaluation of drug selection and dose, and may assess risk of drug-drug interactions for an individual patient. Targeted post-therapeutic drug testing can define the actual drug phenotype, to further optimize drug therapy for that patient. This presentation will review the clinical utility of pharmacogenetics in pain management, and how this type of testing may compliment existing test options and clinical algorithms for drug and dose selection.
Originally presented September 05, 2013 in Las Vegas, Nevada.
Gwendolyn McMillin, PhD, DABCC(CC,TC)
Medical Director, Toxicology, ARUP Laboratories
Co-Medical Director, Pharmacogenetics, ARUP Laboratories
Associate Professor of Pathology, University of Utah School of Medicine
Dr. McMillin is a medical director of the Toxicology laboratories and co-medical director of Pharmacogenetics at ARUP, as well as an associate professor of pathology at the University of Utah School of Medicine. She received her PhD in pharmacology and toxicology from the University of Utah and is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry.